Navigation Links
Using Growth Hormone for Boosting Performances is Hazardous

A 36-year-old professional body-builder who used growth hormone to boost his performance landed up with inflamed liver and enlarged// kidneys according to a report.

He was admitted with chest pain for emergency treatment. He had lost 40 kg in 12 months, during which he had also experienced excessive urination, thirst, and appetite.

He admitted using anabolic steroids for 15 years and artificial growth hormone for the past three. He had also taken insulin, a year after starting on the growth hormone.

This was done to counter the effects of high blood sugar, but he had stopped taking it after a couple of episodes of acute low blood sugar (hypoglycaemia) while at the gym.

Tests revealed that his liver was inflamed, his kidneys were enlarged and that he had very high blood sugar. He was also dehydrated, and diagnosed with diabetes.

He was given intravenous fluids and gradually increasing amounts of insulin over five days, after which he was discharged. His symptoms completely cleared up, and he was no longer diabetic.

The use of growth hormone has steadily risen among amateur athletes and bodybuilders all round the world, say the authors, because it is easy to buy online and difficult to detect in screening tests—unlike anabolic steroids.

The authors believe that this is the first reported case of diabetes associated with the use of high dose growth hormone, and urge anyone taking high doses to regularly check their blood sugar levels.


Page: 1

Related medicine news :

1. Preventing Strokes Using Less Invasive Techniques
2. Using Cholesterol Lowering Drugs Effectively
3. Using herbal remedies with chemotherapy may not be a good idea
4. Teenagers Using Hormones And Dietary Supplements To Good Physique
5. Using Stem Cells To Treat Incontinence In Women
6. Using Eyes As The Line Of Reference For Fetal Brain Imaging
7. Remote Robotic Surgery Using Miniature Robots
8. Driving While Using A Mobile Phone May Be Dangerous
9. Detecting Brain Abnormalities in Babies Using New Brain Scanners.
10. Mobilizing Stem Cells at the Injured Site Using Hyperbaric Oxygen Treatments.
11. Treatment of Sickle Cell Anemia Using Gene Therapy.
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash Moradzadeh ... Man for 2015. , Angeleno Magazine is a division of Modern Luxury, ... 1994, Modern Luxury includes more than 50 magazine titles across 15 major markets. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced today that it has officially launched a sleek, mobile-ready and user-centric redesigned ... his company’s new website clearly outlines the benefits that its SEO services provide ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... has always been a country of choice for global multi-center ... Europe in 2015 were tested in phase II-III clinical ... has always been a country of choice for global multi-center phase III ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: